DYN
NASDAQDyne Therapeutics Inc.
Price$20.86+0.41 (+2.03%)
01:30 PM07:45 PM
News · 26 weeks114-22%
2025-12-282026-06-21
Mix8990d
- SEC Filings46(52%)
- Insider28(31%)
- Other14(16%)
- Leadership1(1%)
Latest news
25 items- PRDyne Therapeutics Appoints Barry Greene to Board of DirectorsWALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more than three decades of biopharmaceutical industry experience and a track record of building and scaling innovative companies from development through commercialization across rare diseases, neuroscience, and oncology. "Dyne is approaching a planned transformation into a commercial biotechnology company. In anticipation of potential product launches and revenue generation, w
- SECDyne Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
- INSIDERDirector Kersten Dirk sold $1,695,689 worth of shares (84,355 units at $20.10) as part of a pre-agreed trading plan (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- PRDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 6 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 126,000 shares of Dyne's common stock at a per share exercise price equal to the closing price of Dyne's common stock
- INSIDERChief Medical Officer Kerr Douglas sold $16,259 worth of shares (887 units at $18.33) as part of a pre-agreed trading plan, decreasing direct ownership by 0.52% to 169,155 units (SEC Form 4) to satisfy tax liability4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Commercial Officer Friedl-Naderer Johanna sold $2,658 worth of shares (145 units at $18.33) as part of a pre-agreed trading plan, decreasing direct ownership by 0.09% to 154,208 units (SEC Form 4) to satisfy withholding obligation4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERCEO & President Cox John sold $49,179 worth of shares (2,683 units at $18.33) as part of a pre-agreed trading plan, decreasing direct ownership by 0.72% to 368,151 units (SEC Form 4) to satisfy tax liability4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECDyne Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
- PRDyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. The transaction further strengthens the company's balan
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- INSIDERSEC Form 4 filed by Director Hurwitz Edward4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Lubner David Charles4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Rhodes Jason P4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Kersten Dirk4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Incerti Carlo4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Stehman-Breen Catherine4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERDirector Posner Brian S bought $33,880 worth of shares (2,000 units at $16.94), increasing direct ownership by 9% to 24,500 units (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECDyne Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
- INSIDERDirector Posner Brian S bought $43,700 worth of shares (2,500 units at $17.48), increasing direct ownership by 12% to 22,500 units (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECDyne Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
- PRDyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the completion of enrollment in the registrational expansion cohort (REC) of the Phase 1/2 ACHIEVE trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in individuals with DM1. "Completing enrollment in the registrational expansion cohort of ACHIEVE is a critical milestone as we advance a potentially best-in-class therapy designed to a
- INSIDERDirector Posner Brian S bought $36,420 worth of shares (2,000 units at $18.21), increasing direct ownership by 11% to 20,000 units (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- PRDyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust and statistically significant increase in dystrophin production with functional improvement observed across multiple clinical endpoints and a favorable safety profile1 - - Proposed dosing regimen of 20 mg/kg administered intravenously once every 4 weeks (Q4W) - WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announc
- INSIDERDirector Posner Brian S bought $42,800 worth of shares (2,500 units at $17.12), increasing direct ownership by 16% to 18,000 units (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- PRDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 17 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 296,500 shares of Dyne's common stock at a per share exercise price equal to the closing price of Dyne's common stock
DYN FAQ
7 questionsWhat does Dyne Therapeutics Inc. do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.Where does DYN stock trade?
Dyne Therapeutics Inc. (DYN) is listed on NASDAQ.What sector and industry is DYN in?
Dyne Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dyne Therapeutics Inc. go public?
Dyne Therapeutics Inc. (DYN) completed its IPO in 2020.What are analysts saying about DYN?
Dyne Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $4000.00 price target on 2025-12-10. Recent price targets range from $1300.00 to $4600.00.What companies are similar to DYN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DYN side-by-side with any of them on Quantisnow.How can I track DYN on Quantisnow?
Quantisnow aggregates Dyne Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DYN to receive live email and push alerts on every new disclosure.